Truist raised the firm’s price target on Scholar Rock (SRRK) to $45 from $36 and keeps a Buy rating on the shares after Biohaven’s (BHVN) Phase 3 study spinal muscular atrophy failed to meet the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results